Foghorn Therapeutics (FHTX) Asset Writedowns and Impairment (2024 - 2025)
Foghorn Therapeutics' (FHTX) quarterly Asset Writedowns and Impairment came in at $5.9 million in Q4 2025, up 294900.0% year-on-year from N/an in Q4 2024, and up 294900.0% quarter-over-quarter from $2000.0 in Q4 2024.
Foghorn Therapeutics (FHTX) Asset Writedowns and Impairment (2024 - 2025) Analysis & Trends
Foghorn Therapeutics' Asset Writedowns and Impairment history runs 2 years deep, the most recent figure standing at $5.9 million for Q4 2025.
- On a quarterly basis, Asset Writedowns and Impairment rose 294900.0% year-over-year to $5.9 million in Q4 2025; TTM through Dec 2025 was $5.9 million, a 145.92% increase from a year earlier, with the FY2025 full-year figure at $5.9 million, up 145.83% from the prior year.
- Asset Writedowns and Impairment improved to $5.9 million in Q4 2025 per FHTX's latest filing, from $2000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $5.9 million in Q4 2025 and bottomed at $2000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - |
| 3 | Akari Therapeutics | 1,021.31 Bn | 1,021.31 Bn | - |
| 4 | BeOne Medicines | 467.89 Bn | 463.10 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.95 Bn | 115.70 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.19 Bn | 61.44 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.46 Bn | 63.46 Bn | - |
| 8 | Argenx Se | 55.64 Bn | 50.45 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn |
| 10 | Foghorn Therapeutics | 345.61 Mn | 256.70 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.90 Mn |
| Dec 31, 2025 | 5.90 Mn |
| Dec 31, 2024 | 2,000.00 |
| Dec 31, 2024 | 2,000.00 |
| Jun 30, 2024 | 2.40 Mn |
| Jun 30, 2024 | 2.40 Mn |